Skip to main content

Kaitai Capital — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

81
Companies
$891.1M
Total invested
$16.8M
Avg. check
34
Industries
Biotechnology 13Pharmaceutical 8Medical 5Health Care 5Biopharma 5Software 5+28 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 25–48 of 81
Xinyue
May 2024

Xinyue is a audio and video asset management and collaborative delivery brand to help users with intelligent audio-video workflow.

Information Technology · Shanghai$1.4M Series A
TechnoDerma Medicines
January 2024

TechnoDerma Medicines is engaged in the research and development of skin drugs for external use.

Biotechnology · XuzhouSeries A
Phanes Therapeutics
January 2024

Phanes Therapeutics is a biotech company focused on discovery and development of therapeutics for solid tumors and eye diseases

Biotechnology · San DiegoSeries Unknown
Ceram Pharmaceuticals
December 2023

Ceram Pharmaceuticals is a biotech firm that uses epigenetics to carry out R&D of drugs and diagnostic treatments for cancer and diseases.

Biotechnology · Shenzhen$14.0M Series A
Atom Bioscience & Pharmaceutical
October 2023

Atom Bioscience is a clinical-stage biotechnology company.

Biotechnology · Suzhou$82.1M Series D
Nafi Pharmaceuticals
September 2023

Nafi Pharmaceuticals develops novel medications for central nervous system illnesses.

Biotechnology · ShenzhenSeries A
Astrocyte Pharmaceuticals
August 2023

Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain injury patients.

Biotechnology · Cambridge$6.0M Series B
CirCode
August 2023

CirCode Bio is an innovative biotechnology company focusing on the development of circular RNA nucleic acid drugs.

Biotechnology · ShanghaiSeries A
Circular Code Biology
August 2023

Ring Code Bio is a biomedical company that develops nucleic acid drugs based on a unique circular RNA technology platform.

Biopharma · ShanghaiSeries A
Hongyun Biotech
May 2023

Hongyun Biotech is a biotech company that promotes therapeutic innovation based on structural pharmacology.

Biotechnology · Nanjing$14.4M Series B
Databaker
April 2023

Databaker is an AI data service company that provides speech synthesis, speech recognition, and image recognition data services.

Artificial Intelligence (AI) · Beijing$14.6M Series B
Primelink Bio
November 2022

Primelink Bio is a Biotechnology firm that is working to to develop next generation of drug delivery systems.

Biopharma · Tongyuan$13.9M Series Unknown
Lupeng Pharmaceutical
November 2022

Lupeng Pharmaceutical is a biotech company that focuses on the drug discovery and development of novel therapies for cancer treatment.

Biotechnology · Guangzhou$35.0M Series A
Realibox
September 2022

Realibox delivers digital designing and cloud platform solutions for enterprises.

3D Technology · Guangzhou$14.0M Series A
Aoquan
August 2022

Aoquan is a biopharmaceutical company that provides research and development, production, and industrialization of innovative drugs.

Biopharma · Shanghai$14.8M Series B
Wangfanxin
July 2022

Wangfanxin is a supplier of business process management software products that support data processing and lean enterprise management.

Big Data · Shanghai$14.8M Series A
Apache DolphinScheduler
July 2022

Apache DolphinScheduler is a distributed and extensible workflow scheduler platform with powerful DAG visual interfaces.

Cloud Computing · Beijing$10.0M Angel
Yiwise
June 2022

Yiwise is a research and development artificial intelligence company.

Artificial Intelligence (AI) · HangzhouSeries B
Worktile
April 2022

Worktile is a Enterprise services Startup Based in Beijing.

Enterprise · Beijing$15.2M Series C
Ke Ning Bio
April 2022

Ke Ning Bio is an ophthalmic pharmaceutical manufacturer dedicated to developing ophthalmic drugs.

Biotechnology · Shenzhen$15.7M Seed
TaoCloud
February 2022

TaoCloud is a software-defined storage solution provider.

Enterprise · Haidian$866K Series C
Bichen Pharmaceutical
January 2022

Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.

Biopharma · Shanghai$30.0M Series B
TianTi Biotherapeutics
December 2021

TianTi Biotherapeutics is a biotechnology company that provides research and development of antibody drugs.

Biopharma · Woburn$15.6M Series A
BioBin Data Science
December 2021

BioBin Data Science is a technology firm specializing in custom software development, big data, and intelligent breeding data platforms.

Agriculture · Changsha$1.6M Seed

Where Kaitai Capital invests

Biotechnology13
Pharmaceutical8
Medical5
Health Care5
Biopharma5
Software5

About Kaitai Capital's portfolio

How many companies has Kaitai Capital invested in?▸

Kaitai Capital has invested in 81 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Kaitai Capital invest in?▸

Kaitai Capital's top investment sectors include Biotechnology, Pharmaceutical, Medical, Health Care, Biopharma. The firm invests across 34 different industry categories.

What is Kaitai Capital's largest investment?▸

Among tracked funding rounds, Atom Bioscience & Pharmaceutical received $82.1M in a Series D round. Kaitai Capital's total known invested capital is $891.1M.

What is the average investment size for Kaitai Capital?▸

Kaitai Capital's average investment size is $16.8M across its portfolio of 81 companies.

What are Kaitai Capital's most recent investments?▸

Recent Kaitai Capital portfolio additions include Xinyue, TechnoDerma Medicines, Phanes Therapeutics, Ceram Pharmaceuticals, Atom Bioscience & Pharmaceutical. These companies were founded in 2020 or later.

Reach the founders behind these 81 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →